Cara, Vi­for Phar­ma score speedy FDA nod on itch­ing drug for CKD — shares surge

The FDA has ap­proved Cara Ther­a­peu­tics and Vi­for Phar­ma’s Ko­r­su­va (dife­like­falin), a nov­el kap­pa opi­oid re­cep­tor ag­o­nist in­jec­tion to treat se­vere-to-mod­er­ate pru­ri­tis, or itch­ing, in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER